Shanghai Desano Pharmaceuticals has contributed to a series B round for the antiviral, cancer and cardiovascular drug developer, which is seeking to list in Hong Kong.

China-based virus, tumour and cardiovascular therapeutics developer Genuine Biotech raised $100m in series B funding today from investors including pharmaceutical firm Shanghai Desano Pharmaceuticals.

Private equity firms Efund Capital and Yingke PE co-led the round, which included consultancy ABC Group’s ABC Capital vehicle and investment firm China Fortune Financial Group.

Founded in 2012, Genuine Biotech is developing therapies intended to treat viral and cardiovascular diseases in addition to cancers. Its lead candidate, Azvudine, targets viruses including HIV and Sars-Cov-2, which…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn